Clinical trials
Cell Therapy clinical trials
Below are recruiting cell therapy clinical trials, each written for real people, not researchers. We’re tracking 1,109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07229729RecruitingPhase 2
Combination therapy for resectable lung cancer
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
Guangzhou, GuangdongAges 18–70 - NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06071637RecruitingPhase 3
Preventing mouth sores with laser therapy in stem cell transplant
This trial tests if a low-power laser can prevent painful mouth sores and throat pain in people getting a stem cell transplant from a donor. The laser is applied to the mouth before sores start, aiming to reduce pain and speed healing.
Rio de Janeiro, Rio de JaneiroAges 18–100 - NCT06879340RecruitingPhase 1
Testing a new CAR-T therapy for B-cell blood cancers
This study tests a new CAR-T cell therapy called DuoCAR20.19.22-D95 for people with certain blood cancers (like lymphoma and ALL) that have come back or haven't responded to multiple treatments. It aims to see if this therapy is safe and can help shrink or control the cancer.
Westwood, KansasAges 18 years+ - NCT03392233RecruitingPhase 2
Targeted radiation for spinal metastases causing significant pain
This trial tests a focused form of radiation (stereotactic body radiation) to treat cancer spread to the spine, especially when it causes substantial pain. It may help shrink or control the spinal spots while limiting damage to surrounding tissues.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT06116786RecruitingPhase 1
Experimental drug JNJ-86974680 for advanced lung cancer
This study tests an experimental drug called JNJ-86974680 for people with advanced non-small cell lung cancer. It looks at how well the drug works, whether you have a gene change or not, and what treatments you've already had.
Newnan, GeorgiaAges 18 years+ - NCT06577311RecruitingPhase 2
Light therapy for facial skin cancer (SCCis)
This study tests a light-activated treatment (photodynamic therapy) for a very early form of skin cancer on the face. It may offer an alternative to surgery.
Aventura, FloridaAges 18 years+ - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07236203Recruiting
Study of CAR-T therapy for relapsed large B-cell lymphoma
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07059221RecruitingPhase 1/Phase 2
New drug combo for advanced head and neck cancer
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07288073RecruitingPhase 2
TIL Therapy for Advanced Skin Cancer Patients
This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.
Boston, MassachusettsAges 18 years+ - NCT03943238RecruitingPhase 1
Kidney transplant with immune therapy to prevent rejection
This trial tests a combination of low-dose radiation, chemotherapy, and donor immune cells to help your body accept a living donor kidney without long-term anti-rejection drugs.
Palo Alto, CaliforniaAges 18–65 - NCT05600842Recruiting
Lower-dose radiation for HPV-positive throat cancer
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
Orange, CaliforniaAges 18 years+ - NCT07147426RecruitingPhase 2
Tislelizumab plus chemo before surgery for head and neck cancer
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05047094Recruiting
DaRT radiation plus pembrolizumab for head and neck cancer
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
JerusalemAges 18 years+ - NCT06934343Recruiting
Personalized therapy for advanced lung cancer using data
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
Salt Lake City, UtahAges Any age - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
La Jolla, CaliforniaAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT04729543RecruitingPhase 1/Phase 2
TCR cell therapy for melanoma and head and neck cancer
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
RotterdamAges 18 years+ - NCT04888338Recruiting
Studying outcomes after CAR-T, radiation, or bispecific therapy
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Houston, TexasAges 18 years+ - NCT07093073RecruitingPhase 1
CAR-T therapy for B-cell lymphoma
This trial tests a new CAR-T cell therapy (called ssCART-19) for people with B-cell lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells to target and kill cancer cells.
ShanghaiAges 2–75 - NCT07103395RecruitingPhase 2
Study of chemo, radiation, and dual immunotherapy for stage 3 lung cancer
This trial tests combining chemotherapy, radiation therapy, and two immune-boosting drugs (iparomlimab and tuvonralimab) as a first treatment for locally advanced non-small cell lung cancer that cannot be surgically removed. It aims to see if this combination improves outcomes compared to standard care.
Guangzhou, GuangdongAges 18–75 - NCT02131753RecruitingPhase 2/Phase 3
Optimizing treatment for hairy cell leukemia in adults
This trial studies the best way to treat hairy cell leukemia and checks how well the approach works in people who need treatment for their disease. It may help if you have classic hairy cell leukemia and have not had certain prior chemotherapy.
AnsbachAges 18–90
Hear when a new Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cell therapy?
- Yes. Clin2 currently lists 1,109 recruiting cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.